Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente

被引:27
作者
Black, S
Lieu, TA
Ray, GT
Capra, A
Shinefield, HR
机构
[1] Kaiser Permanente Vaccine Study Ctr, Oakland, CA 94612 USA
[2] Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Kaiser Permanente, Div Res, Oakland, CA 94612 USA
[5] Kaiser Permanente, Vaccine Study Ctr, Oakland, CA 94612 USA
关键词
otitis media; vaccination; pneumococcus; cost-effectiveness;
D O I
10.1016/S0264-410X(00)00284-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To review studies of the costs of pneumococcal disease and the cost effectiveness of pneumococcal conjugate vaccination conducted in association with the Kaiser Permanente Pneumococcal conjugate Efficacy Trial. Results: for each birth cohort of 3.8 million infants, routine pneumococcal conjugate vaccination program for healthy infants would prevent more than 12 000 (78% of potential) meningitis and bacteremia cases, 53 000 (69% of potential) pneumonia cases, and 1 million (8% of potential) otitis media episodes. Before accounting for vaccine costs, the vaccination program would reduce the costs of pneumococcal disease by $342 million in medical and $415 million in work-loss and other costs. Vaccination of healthy infants would result in net savings for society if the vaccine cost less than $46 per dose, and net savings for the health care payer if the vaccine cost less than $18 per dose. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:S83 / S86
页数:4
相关论文
共 15 条
  • [1] BLACK S, IN PRESS PEDIAT INFE
  • [2] CAPRA AM, IN PRESS PEDIAT INFE
  • [3] Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P23
  • [4] Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P144
  • [5] OTITIS-MEDIA
    KLEIN, JO
    [J]. CLINICAL INFECTIOUS DISEASES, 1994, 19 (05) : 823 - 833
  • [6] LIEU T, IN PRESS J AM MED AS
  • [7] COST-EFFECTIVENESS OF A ROUTINE VARICELLA VACCINATION PROGRAM FOR UNITED-STATES CHILDREN
    LIEU, TA
    COCHI, SL
    BLACK, SB
    HALLORAN, ME
    SHINEFIELD, HR
    HOLMES, SJ
    WHARTON, M
    WASHINGTON, AE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (05): : 375 - 381
  • [8] Bacterial vaccines and serotype replacement:: Lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae
    Lipsitch, M
    [J]. EMERGING INFECTIOUS DISEASES, 1999, 5 (03) : 336 - 345
  • [9] PREVENTION OF HEPATITIS-B VIRUS TRANSMISSION BY IMMUNIZATION - AN ECONOMIC-ANALYSIS OF CURRENT RECOMMENDATIONS
    MARGOLIS, HS
    COLEMAN, PJ
    BROWN, RE
    MAST, EE
    SHEINGOLD, SH
    AREVALO, JA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (15): : 1201 - 1208
  • [10] Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine
    Mbelle, N
    Heubner, RE
    Wasas, AD
    Kimura, A
    Chang, I
    Klugman, KP
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (04) : 1171 - 1176